Oxford Biomedica PLC

Report Publication Announcement • Jan 23, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1376W

Oxford Biomedica PLC

23 January 2013

Oxford BioMedica: Notice of Preliminary Results

Results date: 27 February 2013

Oxford, UK - 23 January 2013: Oxford BioMedica plc (LSE: OXB), the leading gene-based biopharmaceutical company, will be announcing its preliminary results for the twelve months ended 31 December 2012 on Wednesday, 27 February 2013.

An analyst briefing will be held at 09:30am GMT on Wednesday, 27 February 2013 at the offices of M:Communications, 11th Floor, CityPoint, 1 Ropemaker Street, London, EC2Y 9AW. An audio replay will be made available shortly after the presentation on the Company's website: www.oxfordbiomedica.co.uk

-Ends-

For further information, please contact:
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications	Tel: +44 (0)1865 783 000
Media Enquiries: Mary Clark/Sarah Macleod/Claire Dickinson M:Communications	Tel: +44 (0)20 7920 2360

Notes to editors

1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOREAXFAAAEDEFF